These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1346458)

  • 1. Control of emesis in bowel obstruction in terminally ill patients.
    Khoo D; Riley J; Waxman J
    Lancet; 1992 Feb; 339(8789):375-6. PubMed ID: 1346458
    [No Abstract]   [Full Text] [Related]  

  • 2. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction.
    Hisanaga T; Shinjo T; Morita T; Nakajima N; Ikenaga M; Tanimizu M; Kizawa Y; Maeno T; Shima Y; Hyodo I
    Jpn J Clin Oncol; 2010 Aug; 40(8):739-45. PubMed ID: 20410056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient].
    Shima Y; Yamaguchi K; Miyata Y; Hyodo I; Yagi Y; Honke Y
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1377-82. PubMed ID: 15446560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Octreotide in the management of bowel obstruction in terminal ovarian cancer.
    Mangili G; Franchi M; Mariani A; Zanaboni F; Rabaiotti E; Frigerio L; Bolis PF; Ferrari A
    Gynecol Oncol; 1996 Jun; 61(3):345-8. PubMed ID: 8641613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Octreotide in relieving gastrointestinal symptoms due to bowel obstruction.
    Mercadante S; Spoldi E; Caraceni A; Maddaloni S; Simonetti MT
    Palliat Med; 1993; 7(4):295-9. PubMed ID: 7505187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial.
    Mystakidou K; Tsilika E; Kalaidopoulou O; Chondros K; Georgaki S; Papadimitriou L
    Anticancer Res; 2002; 22(2B):1187-92. PubMed ID: 12168923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction.
    Shima Y; Ohtsu A; Shirao K; Sasaki Y
    Jpn J Clin Oncol; 2008 May; 38(5):354-9. PubMed ID: 18490369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.
    Currow DC; Quinn S; Agar M; Fazekas B; Hardy J; McCaffrey N; Eckermann S; Abernethy AP; Clark K
    J Pain Symptom Manage; 2015 May; 49(5):814-21. PubMed ID: 25462210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical efficacy of octreotide acetate in cancer patients with malignant bowel symptoms depend on terminal stage].
    Uchino R; Kusano S; Hanada N; Ohara C; Okino T; Yamaguchi K
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):255-7. PubMed ID: 21368489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained release octreotide may have a role in the treatment of malignant bowel obstruction.
    Massacesi C; Galeazzi G
    Palliat Med; 2006 Oct; 20(7):715-6. PubMed ID: 17060271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neural pathways of emesis associated with experimental intestinal obstruction in dogs.
    Sharma RN; Dubey PC; Dixit KS; Bhargava KP
    Indian J Med Res; 1972 Feb; 60(2):291-5. PubMed ID: 5035199
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful control of vomiting, due to malignant upper gastrointestinal obstruction, by 'blind' percutaneous gastrostomy, in a terminally ill patient.
    Hutchison SM
    Palliat Med; 2008 Jul; 22(5):673-4. PubMed ID: 18612036
    [No Abstract]   [Full Text] [Related]  

  • 13. Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics.
    Weber C; Zulian GB
    Am J Hosp Palliat Care; 2009; 26(2):84-8. PubMed ID: 19088264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Percutaneous endoscopic gastrostomy (PEG) for palliative decompression drainage in inoperable ileus].
    Ritz MA; Arn M; Ballmer PE; Jost R
    Schweiz Med Wochenschr; 2000 Nov; 130(44):1699-701. PubMed ID: 11103445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer.
    Kubota H; Taguchi K; Kobayashi D; Naruyama H; Hirose M; Fukuta K; Kubota Y; Yasui T; Yamada Y; Kohri K
    Asian Pac J Cancer Prev; 2013; 14(12):7107-10. PubMed ID: 24460259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of octreotide in bowel obstruction.
    Mercadante S
    Palliat Med; 1993; 7(1):78. PubMed ID: 8287204
    [No Abstract]   [Full Text] [Related]  

  • 17. Octreotide for malignant bowel obstruction: twenty years after.
    Mercadante S; Porzio G
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):388-92. PubMed ID: 22277783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effective made of octreotide intravenous administration for malignant gastrointestinal obstruction in terminal cancer patients].
    Tanimura K; Onda S; Mitsunobu M
    Gan To Kagaku Ryoho; 2010 Oct; 37(10):1991-3. PubMed ID: 20948271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of treatment-related intermittent partial small bowel obstruction: the use of octreotide.
    Myers J; Tamber A; Farhadian M
    J Pain Symptom Manage; 2010 Apr; 39(4):e1-3. PubMed ID: 20153136
    [No Abstract]   [Full Text] [Related]  

  • 20. SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction.
    Laval G; Rousselot H; Toussaint-Martel S; Mayer F; Terrebonne E; François E; Brixi H; Nguyen T; Bourdeix I; Bisot-Locard S; Zelek L;
    Bull Cancer; 2012 Feb; 99(2):E1-9. PubMed ID: 22265994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.